Vyne Accounts Payable from 2010 to 2024

VYNE Stock  USD 2.97  0.40  15.56%   
Vyne Therapeutics' Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 3.3 M this year. Accounts Payable is the amount Vyne Therapeutics owes to suppliers or vendors for products or services received but not yet paid for. It represents Vyne Therapeutics' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2016-12-31
Previous Quarter
4.5 M
Current Value
M
Quarterly Volatility
2.9 M
 
Covid
Check Vyne Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vyne Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 13 M, Selling General Administrative of 12.7 M or Other Operating Expenses of 58.3 M, as well as many indicators such as Price To Sales Ratio of 53.63, Dividend Yield of 0.0 or PTB Ratio of 0.28. Vyne financial statements analysis is a perfect complement when working with Vyne Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.

Latest Vyne Therapeutics' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Vyne Therapeutics over the last few years. An accounting item on the balance sheet that represents Vyne Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Vyne Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Vyne Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vyne Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

Vyne Accounts Payable Regression Statistics

Arithmetic Mean2,233,904
Geometric Mean1,610,079
Coefficient Of Variation80.78
Mean Deviation1,448,565
Median1,659,000
Standard Deviation1,804,658
Sample Variance3.3T
Range5.9M
R-Value0.69
Mean Square Error1.9T
R-Squared0.47
Significance0
Slope276,746
Total Sum of Squares45.6T

Vyne Accounts Payable History

20243.3 M
20231.7 M
20222.4 M
20216.5 M
20204.8 M
20193.8 M
20183.3 M

About Vyne Therapeutics Financial Statements

Vyne Therapeutics stakeholders use historical fundamental indicators, such as Vyne Therapeutics' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Vyne Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Vyne Therapeutics' assets and liabilities are reflected in the revenues and expenses on Vyne Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Vyne Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable1.7 M3.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Vyne Therapeutics is a strong investment it is important to analyze Vyne Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Vyne Therapeutics' future performance. For an informed investment choice regarding Vyne Stock, refer to the following important reports:
Check out the analysis of Vyne Therapeutics Correlation against competitors.
For information on how to trade Vyne Stock refer to our How to Trade Vyne Stock guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vyne Therapeutics. If investors know Vyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
1.72
Revenue Per Share
0.016
Quarterly Revenue Growth
0.467
Return On Assets
(0.35)
Return On Equity
(0.60)
The market value of Vyne Therapeutics is measured differently than its book value, which is the value of Vyne that is recorded on the company's balance sheet. Investors also form their own opinion of Vyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vyne Therapeutics' market value can be influenced by many factors that don't directly affect Vyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vyne Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.